Connected profiles2
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Breast Cancer peptide evidence brief
A cited Breast Cancer peptide evidence brief across 4 exact-label ClinicalTrials.gov records, 2 connected profiles, and 3 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
4 selected records.
Connected peptides
2 profiles.
Registry update years
2013–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Breast Cancer?
PeptideScanner’s selected collection contains 4 retained ClinicalTrials.gov records carrying the exact condition label “Breast Cancer,” connected to 2 peptide profiles across 3 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Breast Cancer, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases3
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (2)Phase 4 (1)Phase 2 (1)
Registry statuses2
Overall statuses at each retained observation, not necessarily current today.
Completed (3)Recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 111 selected PubMed records and 26 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Breast Cancer unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Breast Cancer.
Leuprolide · source record 2026-06-16
Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.
PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-08-14
Inflammation-mediated facial nodules to compounded tirzepatide.
PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-08-13
Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome.
PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.
PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-08-13
Facial nodules following filler injections after initiating compounded tirzepatide use.
PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT00002580
PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- November 6, 2013
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT00002582
PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- August 2, 2013
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT00903162
PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- April 18, 2016
- Evidence lane
- Clinical trials
Exact-record source chronology
Breast Cancer registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
1 recordTirzepatide · 2026-07-22
ClinicalTrials.gov record NCT07257484
Recruiting at the retained observation.
Open cited registry record →2016
1 recordLeuprolide · 2016-04-18
ClinicalTrials.gov record NCT00903162
Completed at the retained observation.
Open cited registry record →2013
2 recordsLeuprolide · 2013-11-06
ClinicalTrials.gov record NCT00002580
Completed at the retained observation.
Open cited registry record →Leuprolide · 2013-08-02
ClinicalTrials.gov record NCT00002582
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.